AN2 Therapeutics, Inc.(ANTX)

Biotechnology · Menlo Park, CA

$5.61-0.10 (-1.75%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

AN2 Therapeutics (ANTX) EV/FCF: History & Chart | TGMCharts

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T12:05:30.892Z.

Stored calculation inputs

Calculation as of: 2026-10-06T12:05:30.892Z.

Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 202,050,674
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 44,318,000
TTM free cash flow · period ending 2026-06-30: -30,682,000

FMP input reference: 66e3eaee1cdd755dffe0dd2f4d89b3fc137545160e5faabf240127d9674bae42

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ANTX EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

ANTX Competitors' EV/FCF Ratio

ANTX

AN2 Therapeutics, Inc.

Current

Market Cap

$202.05M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ETRA

Electra Therapeutics Inc.

vs ANTX

Market Cap

$206.61M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ELDN

Eledon Pharmaceuticals, Inc.

vs ANTX

Market Cap

$192.97M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CGEN

Compugen Ltd.

vs ANTX

Market Cap

$218.42M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DERM

Journey Medical Corporation

vs ANTX

Market Cap

$184.12M

EV/FCF Ratio

N/A

TTM Avg

72.04x

3Y Avg

55.57x

5Y Avg

55.57x

ALEC

Alector, Inc.

vs ANTX

Market Cap

$220.94M

EV/FCF Ratio

N/A

TTM Avg

2.29x

3Y Avg

2.30x

5Y Avg

3.66x

CNTN

Canton Strategic Holdings Inc

vs ANTX

Market Cap

$179.70M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CUE

Cue Biopharma, Inc.

vs ANTX

Market Cap

$176.96M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DTIL

Precision BioSciences, Inc.

vs ANTX

Market Cap

$174.17M

EV/FCF Ratio

N/A

TTM Avg

277.79x

3Y Avg

277.79x

5Y Avg

277.79x

CHRS

Coherus Oncology, Inc.

vs ANTX

Market Cap

$173.04M

EV/FCF Ratio

N/A

TTM Avg

568.17x

3Y Avg

568.17x

5Y Avg

88.75x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
AN2 Therapeutics, Inc. (ANTX)	$202.05M	N/A	N/A	N/A	N/A
Electra Therapeutics Inc. (ETRA)vs ›	$206.61M	N/A	N/A	N/A	N/A
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$192.97M	N/A	N/A	N/A	N/A
Compugen Ltd. (CGEN)vs ›	$218.42M	N/A	N/A	N/A	N/A
Journey Medical Corporation (DERM)vs ›	$184.12M	N/A	72.04x	55.57x	55.57x
Alector, Inc. (ALEC)vs ›	$220.94M	N/A	2.29x	2.30x	3.66x
Canton Strategic Holdings Inc (CNTN)vs ›	$179.70M	N/A	N/A	N/A	N/A
Cue Biopharma, Inc. (CUE)vs ›	$176.96M	N/A	N/A	N/A	N/A
Precision BioSciences, Inc. (DTIL)vs ›	$174.17M	N/A	277.79x	277.79x	277.79x
Coherus Oncology, Inc. (CHRS)vs ›	$173.04M	N/A	568.17x	568.17x	88.75x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

ANTX EV/FCF Ratio Metrics

ANTX Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics